1421373-36-5

Basic information

• Product Name: 3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamid
• Synonyms: 3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamid;3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamide;3-Chloro-N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]propanamide;3-chloro-N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]propanamide
• CAS NO: 1421373-36-5
• Molecular Formula: C₂₈H₃₄ClN₇O₂
• Molecular Weight: 536.06826
• Mol File: 1421373-36-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• PKA: 13.24±0.70(Predicted)
• CAS DataBase Reference: 3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamid(1421373-36-5)
• EPA Substance Registry System: 3-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamid(1421373-36-5)

Safety Data

• Hazardous Substances Data: 1421373-36-5(Hazardous Substances Data)

Upstream product

• 32338-02-6 2-bromo-4-methoxyaniline 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 107-94-8 chloropropionic acid 
• 1421372-66-8 N?2?[[2?(dimethylamino)ethyl]methylamino]?4?methoxy?5?[[4?(1?methyl?1H?indole-3-yl)-2-pyrimidinyl]amino]aniline 
• 603-76-9 1-methylindole 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 120-72-9 indole 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1421372-94-2 N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine 
• 1421372-67-9 N¹-(2-(dimethylamino)ethyl)-5-methoxy-N¹-methyl-N⁴-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine 
• 625-36-5 2-chloropropionyl chloride 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 

Downstream Products

• 1421373-66-1 N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate 
• 1421373-65-0 [N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)propen-2-amide] 

Relevant articles and documents

Preparation method of antitumor drug AZD9291

The invention relates to a preparation method of an antitumor drug AZD9291. The preparation method comprises the following steps: taking 2-bromo-4-anisidine as a starting raw material; carrying out nitration reaction, grignard reaction, acylation reaction, reduction reaction, grignard reaction and elimination reaction to obtain AZD9291 free alkali. The preparation method disclosed by the inventionhas the beneficial effects of wide source of raw materials, low cost, simple operation, recyclable application of a solvent, low discharge amount of waste liquid, high recovery rate of a product andthe like, and easily realizes industralization.

Preparation method for osimertinib

The invention provides a preparation method for osimertinib. According to the invention, the raw material 3-chloropropionic acid has low toxicity and stable properties and is easily available; reaction conditions are mild; operation is simple; high-yield high-purity osimertinib can be prepared; and the method is suitable for industrial production.

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.